Inhibikase Therapeutics (IKT)
NASDAQ:IKT
Want to see IKT full AI Analyst Report?
IKT Stock Chart & Stats
$1.83
$0.06(1.71%)
At close: 4:00 PM EST
$1.83
$0.06(1.71%)
Day’s Range― - ―
52-Week Range$1.33 - $2.26
Previous CloseN/A
Volume38.02K
Average Volume (3M)132.72K
Market Cap
$241.62M
Enterprise Value$172.24M
Total Cash (Recent Filing)$170.37M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.68
Next Earnings
Aug 17, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.51
Shares Outstanding132,032,640
10 Day Avg. Volume124,469
30 Day Avg. Volume132,718
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)1.17
Price to Sales (P/S)0.00
P/FCF Ratio-7.25
Enterprise Value/Market Cap0.71
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.19
Forecast
1Y Price Target
$6.20Price Target Upside238.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.43
Revenue Forecast (FY)$500.00K
Bulls Say, Bears Say
Bulls Say
Low-debt Balance SheetA near-zero debt profile with a sizable equity base materially reduces near-term refinancing pressure and gives management flexibility to fund R&D and a pivotal trial. This durable capital cushion supports execution of clinical programs over the next several quarters.
Pivotal Phase 3 InitiationLaunching and enrolling a global pivotal Phase 3 is a structural de-risking event: it advances the lead asset toward potential regulatory filing, clarifies required evidence, and can unlock partnership, grant, or financing opportunities tied to trial progress over multiple quarters.
Focused Kinase-inhibitor PipelineA concentrated R&D strategy around kinase inhibitors provides scientific focus and potential differentiation in neurodegenerative and PAH indications. Persistent domain expertise increases odds of program success and makes the company an attractive partner/acquisition target over the medium term.
Bears Say
No TTM RevenueAbsence of product revenue means operations are not self-sustaining and the company must rely on financing to fund development. Over a 2–6 month horizon this structural lack of sales increases execution risk and the likelihood of dilutive capital raises if trial costs persist.
Persistent Cash BurnSustained negative operating and free cash flow indicates the company consumes significant cash to advance trials. Unless offset by external funding or milestone-based inflows, the persistent burn will pressure runway and strategic flexibility, making financing needs a recurring structural issue.
Negative Returns On EquityA very negative ROE shows the capital base is being consumed rather than generating returns. Over medium-term horizons this signals poor capital efficiency and raises concern that shareholders’ equity will be eroded or diluted if the company must repeatedly access external capital to fund development.
Inhibikase Therapeutics News
IKT FAQ
What was Inhibikase Therapeutics’s price range in the past 12 months?
Inhibikase Therapeutics lowest stock price was $1.33 and its highest was $2.26 in the past 12 months.
What is Inhibikase Therapeutics’s market cap?
Inhibikase Therapeutics’s market cap is $241.62M.
When is Inhibikase Therapeutics’s upcoming earnings report date?
Inhibikase Therapeutics’s upcoming earnings report date is Aug 17, 2026 which is in 58 days.
How were Inhibikase Therapeutics’s earnings last quarter?
Inhibikase Therapeutics released its earnings results on May 12, 2026. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.108 by $0.008.
Is Inhibikase Therapeutics overvalued?
According to Wall Street analysts Inhibikase Therapeutics’s price is currently Undervalued.
Does Inhibikase Therapeutics pay dividends?
Inhibikase Therapeutics does not currently pay dividends.
What is Inhibikase Therapeutics’s EPS estimate?
Inhibikase Therapeutics’s EPS estimate is -0.11.
How many shares outstanding does Inhibikase Therapeutics have?
Inhibikase Therapeutics has 132,032,640 shares outstanding.
What happened to Inhibikase Therapeutics’s price movement after its last earnings report?
Inhibikase Therapeutics reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.108. Following the earnings report the stock price went down -1.042%.
Which hedge fund is a major shareholder of Inhibikase Therapeutics?
Currently, no hedge funds are holding shares in IKT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inhibikase Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.20 (238.80% Upside)
$6.20 (238.80% Upside)
Hedge Fund Trend
Decreased
By 3.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 5.4%
Last 30 Days ▼ 5.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.19%
12-Months-Change
Fundamentals
Return on Equity
-41.31%
Trailing 12-Months
Asset Growth
83.85%
Trailing 12-Months
Company Description
Inhibikase Therapeutics
Inhibikase Therapeutics, Inc. operates as a pharmaceutical firm in the clinical development stage, concentrating its efforts on pioneering treatments for Parkinson's Disease (PD) and a range of associated neurological conditions that impact both the brain and other parts of the body. The company's investigational pipeline includes IkT-148009, a small molecule designed to inhibit Abelson tyrosine kinase. This candidate aims to address not only Parkinson's disease itself but also early-stage gastrointestinal complications often experienced by PD patients, such as swallowing difficulties (dysphagia), neurologically-induced constipation, and multiple system atrophy. Additionally, Inhibikase is advancing IkT-001Pro through preclinical development. This prodrug, derived from the anti-cancer agent Imatinib, is intended to lessen typical gastrointestinal side effects while providing treatment for blood and stomach cancers. Beyond these primary compounds, the company is also pursuing various research programs focused on other neurological disorders. Inhibikase actively collaborates on research and development initiatives with several prominent academic institutions, including The Johns Hopkins University, Arizona State University, Michigan State University, and Louisiana State University. Established in 2008, Inhibikase Therapeutics, Inc. maintains its corporate headquarters in Atlanta, Georgia.
IKT Stock 12 Month Forecast
Average Price Target
$6.20
▲(238.80% Upside)
Technical Analysis
Atossa Therapeutics
―
Anixa Biosciences
―
Spero Therapeutics
―
Surrozen
―
TScan Therapeutics
―
Ownership Overview
12.28% Insiders
4.98% Mutual Funds
67.41% Other Institutional Investors
8.28% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---